Jim Heppell, President and Partner

Over the last twenty years, Jim has acted as a director, officer or advisor to approximately one-third of the life science companies that have spun out of BC universities. Jim was co-founder, CEO and Fund Manager of the Advantage Life Science Fund I, which received the “2006 Deal of the Year” Award from the Canada Venture Capital Association for having the highest realized return of any Canadian venture fund that year (23.4X its investment in Aspreva Pharmaceuticals). Advantage Life Science fund I has also posted the highest five year returns of any retail venture fund in Canada.

Jim is Chairman of the Board of Inovio Biomedical, director of Protox Pharmaceuticals and Urodynamix Technologies, and director of a number of private life science companies.  Jim has a Bachelor of Science degree in Microbiology and an LL.B. from the University of British Columbia.